Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder

Next Previous
Trial Profile

Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyproheptadine+prazosin (Primary)
  • Indications Alcoholism
  • Focus Proof of concept; Therapeutic Use
  • Acronyms COCKTAIL
  • Sponsors Kinnov Therapeutics

Most Recent Events

  • 14 Mar 2022 Status changed from active, no longer recruiting to completed.
  • 10 Sep 2021 Planned primary completion date changed from 31 Oct 2021 to 15 Nov 2021.
  • 30 Aug 2021 According to a Kinnov Therapeutics media release, This study was conducted in 34 study centers across France and supervised by its principal investigator, Professor Henri-Jean Aubin (Paul Brousse Hospital, Villejuif). The first results of the study are expected in the first quarter of 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top